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Comparison of Uncultured Marrow Mononuclear Cells
and Culture-Expanded Mesenchymal Stem Cells
in 3D Collagen-Chitosan Microbeads
for Orthopedic Tissue Engineering
Joel K. Wise, PhD,1 Andrea I. Alford, PhD,2 Steven A. Goldstein, PhD,1,2 and Jan P. Stegemann, PhD1
Stem cell-based therapies have shown promise in enhancing repair of bone and cartilage. Marrow-derived
mesenchymal stem cells (MSC) are typically expanded in vitro to increase cell number, but this process is
lengthy, costly, and there is a risk of contamination and altered cellular properties. Potential advantages of using
fresh uncultured bone marrow mononuclear cells (BMMC) include heterotypic cell and paracrine interactions
between MSC and other marrow-derived cells including hematopoietic, endothelial, and other progenitor cells.
In the present study, we compared the osteogenic and chondrogenic potential of freshly isolated BMMC to that
of cultured-expanded MSC, when encapsulated in three-dimensional (3D) collagen-chitosan microbeads. The
effect of low and high oxygen tension on cell function and differentiation into orthopedic lineages was also
examined. Freshly isolated rat BMMC (25 · 106 cells/mL, containing an estimated 5 · 104 MSC/mL) or purified
and culture-expanded rat bone marrow-derived MSC (2 · 105 cells/mL) were added to a 65–35wt% collagen-
chitosan hydrogel mixture and fabricated into 3D microbeads by emulsification and thermal gelation. Mi-
crobeads were cultured in control MSC growth media in either 20% O2 (normoxia) or 5% O2 (hypoxia) for an
initial 3 days, and then in control, osteogenic, or chondrogenic media for an additional 21 days. Microbead
preparations were evaluated for viability, total DNA content, calcium deposition, and osteocalcin and sulfated
glycosaminoglycan expression, and they were examined histologically. Hypoxia enhanced initial progenitor cell
survival in fresh BMMC-microbeads, but it did not enhance osteogenic potential. Fresh uncultured BMMC-
microbeads showed a similar degree of osteogenesis as culture-expanded MSC-microbeads, even though they
initially contained only 1/10th the number of MSC. Chondrogenic differentiation was not strongly supported in
any of the microbead formulations. This study demonstrates the microbead-based approach to culturing and
delivering cells for tissue regeneration, and suggests that fresh BMMC may be an alternative to using culture-
expanded MSC for bone tissue engineering.
Introduction
Repair and healing of critical-sized bone and severearticular cartilage defects is a major clinical challenge in
orthopedics. Current clinical therapies for bone and cartilage
regeneration are hampered by limited availability of auto-
graft tissue and inconsistent effectiveness of allogeneic and
biomaterial-based approaches. Stem cell-based therapies
have shown promise in enhancing bone and cartilage repair.
Marrow-derived mesenchymal stem cells (MSC) have shown
promise in these applications and are of particular interest
due to their ability to self-renew and demonstrated multi-
potency.1–6 In addition, it has been suggested that MSC exert
important trophic effects,7 and immunomodulatory proper-
ties8,9 that make them attractive for cellular therapies.
Culture-expanded MSC are typically used in stem cell-
based therapy due to the now well-established culture
methods that allow plastic-adherent MSC to be easily ma-
nipulated and expanded to produce large quantities for
proposed clinical applications. However, major disadvan-
tages of in vitro culture expansion of MSC include the
lengthy time and large cost, and risk of contamination.
Further, two-dimensional (2D) culture-expanded MSC
in vitro have been shown to exhibit altered antigenic and
gene expression,10–14 loss of expression of cell surface adhe-
sion-related chemokine receptors (CXCR4) that are impera-
tive for homing and engraftment in vivo,15–19 and loss of
multipotential differentiation capacity,20–22 compared with
fresh uncultured MSC. Potential advantages of using fresh
uncultured bone marrow progenitor cells in tissue
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engineered constructs include the maintenance of hetero-
typic cell and paracrine interactions between MSC and other
marrow-derived cells, including hematopoietic stem cells
(HSC), hematopoietic progenitor cells (HPC), and endothe-
lial progenitor cells (EPC).23–26 In addition, unpurified mar-
row fractions may contain osteogenic proteins that can be
incorporated into biomaterials and scaffolds.27
Several previous studies have investigated direct seeding
of freshly isolated uncultured bone marrow cells into three-
dimensional (3D) biomaterials for bone and cartilage tissue
engineering. In an ectopic implantation model in mice, direct
seeding and expansion of uncultured human28 or sheep29
bone marrow mononuclear cells (BMMC) into 3D hydroxy-
apatite-ceramic scaffolds under perfusion resulted in en-
gineered constructs that formed significantly more bone
tissue than scaffolds loaded with 2D culture-expanded bone
marrow-derived MSC. Additionally, it was found that the
osteogenic capacity of engineered bone implants was linked
to the property of clonogenicity of expanded MSC originat-
ing from directly seeded bone marrow aspirate cells.30 In a
critical-sized cranial defect in the rat, porous poly(L-lactic
acid) scaffolds laden with uncultured BMMC encapsulated
within fibrin gel regenerated significantly greater bone vol-
ume than cell-free controls.27 Other recent studies have
shown that 3D ceramic scaffolds directly seeded with autol-
ogous sheep bone marrow cells/MSC12 or unprocessed hu-
man bone marrow31 resulted in similar osteogenic potential
and comparable bone formation in subcutaneous ectopic im-
plantation models, compared with the same scaffolds seeded
with culture-expanded MSC. In contrast to these reports, it
has been reported that in vitro culture-induced osteogenic
differentiation of purified human bone marrow-derived MSC
seeded onto b-tricalcium phosphate ceramics significantly
enhanced subsequent ectopic bone formation, compared with
samples implanted with culture-expanded but undifferenti-
ated MSC or directly seeded fresh uncultured BMMC,32
however, the authors of this study state that only 27% of the
BMMCs were able to initially adhere to the particular type of
scaffolds used. Another study showed that transplantation of
autologous uncultured BMMC, and possibly uncultured pe-
ripheral blood-derived mononuclear cells, within fibrin gels
contributed to the repair of large full-thickness articular car-
tilage defects.33 Additionally, it was recently reported that
uncultured BMMC contribute to the repair of full-thickness
chondral defects with collagen Type II hydrogel as scaffolds,
which had comparable results with culture-expanded bone
marrow-derived MSCs.34
Our group has used 3D hydrogel microbeads to encap-
sulate MSC and other progenitor cells for orthopedic tissue
engineering applications. Three-dimensional microbeads of
a defined size and composition, specifically consisting of
a collagen-based matrix, can provide a protective and in-
structive microenvironment that mimics physiological as-
pects of in vivo conditions. The 3D microbead matrix
surrounding the cells contributes to cell viability mainte-
nance, and the composition of the matrix can be tailored to
promote cell adhesion, proliferation, and/or desired differ-
entiation.35–37 A main advantage of the microbead format is
that cells (either freshly isolated or culture-expanded) can be
directly embedded in microbeads, and they can then be
cultured in suspension in the desired medium type until
needed for delivery. Importantly, the microbeads can then be
collected without trypsinization of the cells, and can be in-
jected as a paste in a minimally invasive manner.38,39 Our
group has previously shown that collagen and chitosan
composite hydrogels fabricated by thermal gelation and
initiation using b-glycerophosphate have strong potential as
matrices for cell encapsulation and scaffolds for bone tis-
sue engineering,40 and that cross-linking with glyoxal can
be used to reinforce the mechanical properties of the gel,
while maintaining cytocompatibility.41 Other investigators
have also investigated the use of MSC encapsulated within
collagen-based microspheres42 for bone,43 cartilage,44,45 and
osteochondral46 tissue engineering.
Bone marrow, one of the main reservoirs of MSC, is esti-
mated to have in vivo oxygen tension in the range of 4%–7%,
much lower than the atmospheric oxygen tension (20%) used
for standard cell culture.47–49 It has been reported that rat
bone marrow-derived MSC exhibited a significantly in-
creased number of colony-forming unit-fibroblasts (CFU-F)
at primary culture, and a 40% higher cell number at first
passage under hypoxia (5% O2) compared with normox-
ia.47,48 In another study, human MSC cultured in normoxia
for 30 days exhibited a decrease in CFU-F number, compared
with a significant increase in CFU-F number in hypoxia (2%
O2), suggesting that hypoxic conditions may selectively fa-
cilitate the survival of more primitive MSC cells.50 It has also
been reported that early stage culture in 5% O2 has a stim-
ulatory effect on rat marrow MSC, as evidenced by signifi-
cantly increased cell proliferation, decreased apoptosis and
necrosis, and decreased expression of hematopoietic mark-
ers.51 Further, it has been shown that hypoxic conditions
enhance the osteoblastic52,53 and chondrogenic54,55 differenti-
ation of bone marrow-derived MSC. The differing effects of
hypoxia on MSC phenotype seen in previous studies empha-
size the complexity of the progenitor cell microenvironment.
The present study compares the osteogenic and chondro-
genic capacity of a mixed cell population (BMMC, which
contains MSC, HSC, and EPC) to that of purified, culture-
expanded MSC, when encapsulated in a collagen-chitosan
hydrogel matrix. It is motivated by the incomplete under-
standing of how accessory cells and oxygen tension may
affect MSC function in the stem cell niche, and how this may
translate to therapeutic effect. The BMMC preparation con-
tains cells and biochemical factors that may have paracrine
effects on the MSC component of the marrow. In contrast,
the MSC preparation is highly purified and therefore has a
higher content of mesenchymal progenitor cells, which are
known to be responsible for regeneration of orthopedic tis-
sues. Both cell types are embedded in protein-polysaccharide
microbeads that enable 3D culture in a controlled and
physiologically relevant environment, and the effect of oxy-
gen tension on osteogenic and chondrogenic differentiation
is also assessed. This study therefore provides insight into
the relative advantages and limitations of fresh marrow
suspensions and purified progenitor cell populations for
orthopedic repair applications.
Materials and Methods
Rat bone marrow-derived MSC
Four Sprague-Dawley rats (3–6 weeks old) were eutha-
nized using carbon dioxide inhalation prior to harvesting
both femur and tibia. The distal and proximal ends of each
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femur and tibia were removed and the marrow was flushed
out with sterile culture media. A single cell suspension was
prepared by mechanical disruption and filtered using a 70-
mm cell strainer.56 BMMC were plated at 5· 105 cells/cm2 in
75 cm2 polystyrene cell culture flasks (BD Falcon), and cul-
tured in MSC growth media consisting of a-MEM (Gibco),
10% fetal bovine serum (FBS; HyClone MSC screened), and
penicillin (5000 units/100mL)/streptomycin sulfate (5mg/
100mL) (P/S; Gibco). Cultures were incubated at 37C in
20% O2 + 5% CO2 (normoxia). Media were changed every 3–4
days and rat marrow-derived adherent MSC were culture
expanded until passage 4, at which point cells were used for
hydrogel microbead experiments. Prior to seeding passage 4
MSC into hydrogel microbeads, cell numbers were counted
using a Multisizer 3 Coulter Counter (Beckman Coulter).
Freshly isolated uncultured rat BMMC
A single cell suspension was obtained from an additional
four Sprague-Dawley rats as outlined above. Red blood cells
(RBCs) were lysed using an ammonium chloride-based lysis
buffer solution57–59 containing 150mM NH4Cl (Sigma),
10mM KHCO3 (Sigma), and 0.1mM EDTA (Sigma). A fresh
rat bone marrow cell solution in 20mL of MSC growth me-
dia was mixed with 60mL of RBC lysis buffer (1:3 dilution)
for 7min at room temperature. Cells were centrifuged at
3500 rpm for 2min, washed with sterile phosphate-buffered
saline (PBS), and the collected BMMC were resuspended in
20mL of MSC growth media. For CFU-F analysis, 150 mL of
this BMMC solution was pipetted into a six-well plate and
cultured in 20% O2+ 5% CO2 (normoxia) or 5% O2+ 10% CO2
(hypoxia) for 2 weeks with media changes every 3 days, to
result in an adherent layer of marrow-derived MSC CFU-F
on day 14. These samples were washed with PBS, fixed with
10% buffered formalin (Anatech Ltd.), stained with 1% To-
luidine Blue O (Sigma) stain, scanned, and counted for col-
ony number. Prior to directly seeding fresh uncultured
BMMC into hydrogel microbeads, BMMC numbers were
counted using a Multisizer 3 Coulter Counter, centrifuged
at 200g for 5min, and then resuspended in MSC growth
media.
Fabrication of 3D collagen-chitosan hydrogel
microbeads containing cells
Collagen-chitosan (mass ratio 65%/35%) hydrogel prepa-
rations of 6mL total initial volume were mixed with each
freshly isolated BMMC collection (passage 0, n = 4) or cul-
ture-expanded rat marrow-derived MSC (passage 4, n= 4).
Each collagen-chitosan hydrogel preparation consisted of
3000 mL collagen type 1 (4mg/mL in 0.02N acetic acid, from
calf skin; MP Biomedicals, cat# 150026, final concentra-
tion = 2mg/mL), 330 mL chitosan (2% w/v in 0.1N acetic
acid, Protosan UP B 90/500; FMC BioPolymer/Novamatrix,
lot# 1148013, final concentration = 0.11% w/v), 730 mL b-
glycerophosphate (580mg/mL in water; Sigma, cat# G9891,
final concentration = 7.1% w/v = 326.7mM), 70mL Glyoxal
(87.5mM in water; Sigma, cat# 128465, final concentra-
tion = 1mM), and 1870 mL of cell solution in MSC growth
media. All components were kept on ice and pipetted to-
gether to result in a total volume of 6mL of collagen-chitosan
hydrogel mixture containing cells. Freshly isolated rat mar-
row-derived BMMC were added into the hydrogel mixture
at an average (n= 4) concentration of 25.3 · 106 BMMC/mL,
whereas culture-expanded marrow-derived MSC (passage 4,
n = 4) were added into the hydrogel mixture at a concentra-
tion of 5· 105 MSC/mL. Microbeads were fabricated by a
water-in-oil emulsion method. Briefly, 6mL of hydrogel-cell
mixture was injected at a rate of 6mL/min into 75mL of
polydimethylsiloxane (PDMS) (PMX-200, 100 cS; Xiameter)
under constant stirring using a mixing apparatus (Barnant
Co.) with a custom impeller. Emulsification was carried out
by mixing at 800 rpm while the PDMS was maintained cold
in a crushed ice bath for 5min. Once the liquid matrix
droplets were fully emulsified and homogenously mixed,
the PDMS bath was transferred to a water bath at 37C for
25min with constant stirring, to initiate thermal gelation
and to achieve co-polymerization of collagen-chitosan mi-
crobeads. The resulting cell-encapsulating microbeads were
collected from the PDMS phase by centrifugation at 200 g
for 5min and washed thrice with MSC growth media and
centrifugation.
Microbead culture in osteogenic or chondrogenic
differentiation media in normoxic or hypoxic conditions
Fabricated collagen-chitosan microbeads containing cells
were resuspended in 12.0mL of MSC growth media, and
distributed evenly in twelve 15mL centrifuge tubes by pi-
petting 1.0mL of microbead/media solution into each tube
and adding an additional 2.0mL of MSC growth (control)
media for culture. Six tubes of cell-microbeads were cultured
in 20% O2+ 5% CO2 (normoxia), while the other six tube
samples were cultured in 5% O2 + 10% CO2 (hypoxia) for an
initial 3 days, with tube caps loosened to allow free gas ex-
change. Subsequently, culture media were changed for all
tube samples by centrifuging at 200 g for 5min, aspirating
media from collected microbeads, and adding 1.5mL of ei-
ther MSC growth media, osteogenic differentiation media, or
chondrogenic differentiation media to appropriate tube
samples. The time point at which these media were added
was designated as day 0. Osteogenic differentiation media
consisted of control media (a-MEM, 10% FBS, and 1% P/S)
supplemented with 0.2mM l-ascorbic acid 2-phosphate
(Sigma), 10mM b-glycerophosphate (Sigma-Aldrich), and
100 nM dexamethasone (Sigma). Chondrogenic differentia-
tion media consisted of DMEM with high glucose (4.5mg/
mL) and 1mM sodium pyruvate (Gibco), l-glutamine
(4mM, Gibco), 1% FBS, 1% P/S, 1% ITS + Universal Culture
Supplement Premix (BD Biosciences), 0.2mM l-ascorbic acid
2-phosphate (Sigma-Aldrich), 0.35mM l-proline (Sigma),
10 ng/mL rhTGF-b1 (Peprotech), and 100 nM dexametha-
sone (Sigma). All culture media were changed every 3 days,
by centrifugation of microbeads at 200 g for 5min, aspiration
of used media, and replenishment with 1.5mL of fresh me-
dia. This medium change protocol did not cause any changes
in cell viability or morphology.
Imaging and characterization of cell viability
and microbeads
At days 1 and 21, cell viability within microbeads was
assessed using a commercially available vital staining kit
(Live/Dead Viability/Cytotoxicity Assay Kit; Molecular
Probes). A sample of microbeads in 50 mL of culture media
(from total of 1.5mL) was obtained and wash twice in
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sterile PBS for 10min, then incubated at 37C for 45min in a
solution containing 4.0 mm calcein-AM and 4.0 mm ethidium
homodimer-1 in PBS. Briefly, calcein-AM diffuses across the
membrane of live cells and reacts with intracellular ester-
ases to emit bright green fluorescence, while ethidium
homodimer-1 can enter only dead cells with damaged cell
membrane and emit bright red fluorescence upon bind-
ing to nucleic acids. After two subsequent PBS washes and
resuspension in 100 mL of PBS, microbeads were imaged
using laser scanning confocal microscope (Olympus Fluo-
View 500; Olympus America, Inc.). At least three different
and random views of dispersed microbeads were imaged at
z-resolution of 3 mm, using FITC (ex = 494 nm, em = 517 nm)
and PI (528/617 nm) filters. Cell viability in three repre-
sentative views was quantified using ImageJ Software
(National Institutes of Health) to give percentages of live
and dead cells from the total number of cells quantified for
each sample. Microbead samples at day 21 were imaged
with phase contrast using an inverted microscope (Nikon
Eclipse Ti-U; Nikon) to show morphology, size, and shade
of microbeads.
DNA assay
Microbead samples (n = 4) were washed with PBS and
digested in 275 mL of 1.0N 50mM Tris-HCl/4M Guanidine-
HCl buffer (pH = 7.5) for 1.5 h at 4C. A commercially
available DNA assay kit (Quanti-iT PicoGreen dsDNA
kit; Invitrogen) was used following the manufacturer’s pro-
tocol to quantify total DNA content from microbead sam-
ples. Briefly, duplicate samples of 50mL of digested sample
solution or DNA standards were incubated with 150 mL of
1 ·PicoGreen reagents and then used for fluorescence mea-
surements at 485/518 nm (excitation/emission).
Calcium assay
Microbead samples (n = 4) were washed with PBS and
digested in 275mL of 1.0N acetic acid overnight at 4C. For
calcium quantification, an orthocresolphthalein complex one
(OCPC) method was used as previously described.40,41,60
Briefly, duplicate samples of 50 mL of digested sample solu-
tion or calcium standard solution (CaCl2; Sigma) was mixed
with 250 mL of working solution consisting of 0.05mg/mL
OCPC solution and ethanolamine/boric acid/8-hydroxyquinoline
buffer (Sigma), incubated for 10min at room temperature,
and used for absorbance measurements at 575 nm.
Osteocalcin rat ELISA
Microbeads samples were washed with PBS and digested
in 275mL of 0.2N HCl overnight, followed by neutralization
with 10N NaOH. A commercially available rat osteocalcin
enzyme immunoassay (EIA) kit (Biomedical Technologies,
Inc.) was used to quantify total protein content of osteocalcin,
a specific protein product of osteoblasts,61 from microbead
samples (n= 4 for osteogenic, n= 2 for growth). The sandwich
ELISA kit is specific for both carboxylated and decarboxylated
rat osteocalcin and was used following the manufacturer’s kit
protocol. In brief, duplicate samples of 25mL of digested
sample solution or osteocalcin standard were used in the
ELISA plate assay, and within 15min of adding stop solution
to all wells, absorbance was measured at 450nm.
Sulfated glycosaminoglycan/1,9-dimethylmethylene
blue assay
Microbeads were washed with PBS and digested over-
night at 65C in 275 mL of papain extraction solution
(pH = 7.5) consisting of 0.2M sodium phosphate dibasic
(Sigma), 0.1M sodium acetate (Sigma), 0.01M disodium
EDTA (Sigma), 5mM l-cysteine HCl monohydrate (Sigma),
and 20 mg/mL of crystallized papain suspension (Sigma).
Sulfated glycosaminoglycan (sGAG) from the digested sample
solution (n= 4 for osteogenic and n= 2 for growth) was mea-
sured using a modification of the 1,9-dimethylmethylene blue
(DMMB) dye assay developed by Farndale et al.62 Briefly,
duplicate samples of 25mL of samples and chondroitin sulfate
standards (Sigma) were mixed with 200mL of DMMB (Sigma)
dye solution and the absorbance was immediately measured
at 525nm.
Histology
Microbead samples were fixed in Z-Fix (buffered zinc
formalin fixative; Anatech Ltd.) for 24 h and stored in 70%
ethanol at 4C. Microbead samples were embedded in col-
lagen-based hydrogel discs using customized Delrin rings of
9.5mm diameter and 3.2mm thickness. Briefly, microbeads
were mixed with 50mL of 1· DMEM, 50mL of FBS, 100 mL of
5·DMEM, 50mL of 0.1 NaOH, and 250 mL of collagen type 1
solution (4mg/mL in 0.02N acetic acid, from calf skin; MP
Biomedicals, cat# 150026, final concentration = 2mg/mL),
while kept on ice. Collagen hydrogel discs were formed by
pipetting 200mL of gel mixture in each ring and incubation at
37C for 45min. Gel discs were placed in tissue histology
cassettes, fixed for 24 h, and stored in 70% ethanol at 4C.
Microbead-containing gel discs were processed and embed-
ded in paraffin and sectioned at 7 mm. Sections were stained
with hematoxylin and eosin (H&E), Alizarin Red S (2%) for
calcium deposits, von Kossa (1% silver nitrate, 5% sodium
thiosulfate) for phosphate component of mineralization, and
safranin-O (0.1%)/fast green (0.05%).
Statistical analyses
Data are reported as mean– standard deviation for DNA
and calcium assays, to aid in visual appearance of small error
bars within these graph figures. Data are reported as
mean– standard error of the mean for osteocalcin and sGAG
assays. Data were analyzed with Student’s t-test and statis-
tical significance was defined by statistical probability of
p£ 0.05.
Results
Characterization of marrow-derived MSC/CFU-F
and culture-expanded MSC
Colonies of MSC (MSC/CFU-F) originating from freshly
isolated rat BMMC (n = 4) were plated in wells of a six-well
plastic plate, cultured for 14 days in MSC growth media, in
either normoxia or hypoxia, and then fixed, stained, and
scanned. Numbers of CFU-F from each well image were
counted using ImageJ. Compared to the normoxic cul-
ture condition (Fig. 1A, average of 39– 6CFU-F), hypoxic
culture resulted in a statistically significant ( p = 0.04) increase
in CFU-F number (Fig. 1B, average of 66 – 5CFU-F).
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FIG. 1. Morphology of fresh rat
bone marrow-derived mesenchy-
mal stem cells (MSC)/colony-
forming unit-fibroblasts (CFU-F)
(passage 0) or culture-expanded rat
bone marrow-derived culture-
expanded MSC (passage 4). CFU-F
of MSC originating from freshly
isolated rat bone marrow-derived
cells cultured for 14 days in vitro in
(A) 20% oxygen normoxia or (B) 5%
oxygen hypoxia. Images were ob-
tained to show morphology of (C)
MSC (passage 0) from CFU-F cul-
tured for 14 days in growth media,
originating from freshly isolated rat
marrow and (D) culture-expanded
rat marrow-derived MSC (passage
4) prior to use in hydrogel mi-
crobead experiments. Scale bar =
500 mm. Color images available
online at www.liebertpub
.com/tea
FIG. 2. Phase-contrast im-
ages of fresh bone marrow
mononuclear cells (BMMC)-
or MSC-microbeads at day
21. BMMC-microbeads were
cultured in normoxia (A–C)
in (A) MSC growth media,
(B) osteogenic media, and (C)
chondrogenic media, or hyp-
oxia (D–F) in (D) MSC
growth media, (E) osteogenic
media, and (F) chondrogenic
media. MSC-microbeads
were cultured in normoxia
(G–I) in (G) MSC growth
media, (H) osteogenic media,
and (I) chondrogenic media,
or hypoxia ( J–L) in ( J) MSC
growth media, (K) osteogenic
media, and (L) chondrogenic
media. Scale bar= 200 mm.
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Cells within a 14-day cultured CFU-F, from the well plate
shown in Figure 1A, were imaged with phase-contrast micros-
copy and showed typical MSC morphology (Fig. 1C). Culture-
expanded rat marrow-derived MSC (passage 4) (Fig. 1D) were
also imaged with phase-contrast microscopy prior to use in
hydrogel microbead experiments. Both fresh marrow-derived
MSC and culture-expanded MSC exhibited similar spread,
spindle-like or fibroblastic morphologies, on a similar scale.
Morphology of collagen-chitosan microbeads
containing cells after 21 days of culture
Collagen-chitosan microbeads encapsulating either fresh
BMMC (Fig. 2A–F) or culture-expanded MSC (Fig. 2G–L)
and cultured in vitro for 21 days were imaged by phase-
contrast microscopy. Microbead samples were cultured in
normoxic (20% oxygen) or hypoxic (5% oxygen) conditions,
in culture media specific for MSC growth, osteogenic dif-
ferentiation, or chondrogenic differentiation, as indicated
in Figure 2. Collagen-chitosan microbeads were generally
spheroidal in shape, and microbeads from each sample
condition had diameters in the range of *100–200 mm. No
degradation of the microbead matrix was observed and all
preparations remained intact over time in culture. Micro-
beads cultured in osteogenic media were generally more
opaque than in other conditions, with a portion appearing
notably dark in color, presumably due to mineral deposition.
Cell viability and quantification within microbead
samples at day 1 and 21
The proportion of live and dead cells out of the total number
of cells quantified in three representative confocal fluorescence
image views for each sample condition on day 1 and 21 are
summarized in Table 1. Representative confocal fluorescence
images of cell viability for BMMC-microbeads at day 1 (Fig.
3A–F) and day 21 (Fig. 4A–F), and for MSC-microbeads at day
1 (Fig. 3G–L) and day 21 (Fig. 4G–L) were obtained.
BMMC-microbeads cultured in normoxia (Fig. 3A–C)
at day 1 in growth, osteogenic, and chondrogenic media
contained a mixture of live (green) and dead (red) cells (32%–
42% viable), whereas BMMC-microbeads cultured in hyp-
oxia (Fig. 3D–F) contained notably more live cells than dead
cells (51%–57% viable). Cell viability in MSC-microbeads
cultured in normoxia and hypoxia at day 1 in growth, os-
teogenic, and chondrogenic media was uniformly high
(83%–94% viable) (Fig. 3G–L). The majority of all cells en-
capsulated in collagen-chitosan microbeads at day 1 (Fig. 3)
have a rounded morphology, although some cells can be
observed as slightly spread, particularly in the samples with
culture-expanded MSC.
At day 21, the proportion of living cells in BMMC-
microbeads cultured in growth or osteogenic media, either
in normoxia or hypoxia, markedly increased to 61%–85%
(Fig. 4A–E), depending on condition. Spreading of live cells
within the collagen-chitosan microbeads was evident in the
growth media/hypoxia (Fig. 4D), osteogenic/normoxia
(Fig. 4B), and osteogenic/hypoxia (Fig. 4E) conditions. Cells
in the growth media/normoxic (Fig. 4A) condition re-
mained rounded. Interestingly, BMMC-microbeads cul-
tured for 21 days in chondrogenic media exhibited very
marked cell death, with only 3% viable cells in normoxia
(Fig. 4C), and a slightly higher number of rounded viable
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cells (13%) in hypoxia (Fig. 4F). In contrast, cell viability in
MSC-microbeads at day 21 (Fig. 4G–L) remained high
(72%–94% viable) under all culture conditions. Cell spreading
within the collagen-chitosan microbead matrix was more
evident in growth (Fig. 4G, J) and osteogenic media cultures
(Fig. 4H, K).
Quantification of total DNA content in microbeads
Figure 5 shows the total DNA content measured in
BMMC- or MSC-microbeads cultured in control MSC
growth media (Fig. 5A or D), osteogenic media (Fig. 5B or
E), or chondrogenic media (Fig. 5C or F), either in normoxia
or hypoxia. At day 1, BMMC-microbeads cultured in
normoxia contained the highest DNA content, whereas
BMMC-microbeads cultured in hypoxia showed signifi-
cantly reduced DNA content, compared to normoxia (Fig.
5A–C). All MSC-microbeads (Fig. 5D–F) contained a much
lower DNA content ( < 10 mg) than BMMC-microbeads be-
cause the purified cells were seeded at a much lower total
cell concentration (5.0 · 105 cells/mL) than the fresh mar-
row preparation (25.3 · 106 cells/mL). By day 21, BMMC-
microbeads cultured in all media and oxygen conditions
exhibited a marked reduction in DNA, relative to day 1
(Fig. 5A–C). There was no significant change in average
DNA content in MSC-microbeads, compared to day 1
samples (Fig. 5D–F).
Quantification of total calcium content
from microbead samples
Figure 6 shows the total calcium content measured in
BMMC- or MSC-microbeads, cultured in normoxia or hyp-
oxia, in control MSC growth media (Fig. 6A), osteogenic
media (Fig. 6B), or chondrogenic media (Fig. 6C). At day 1,
all samples exhibited calcium levels less than 200 mg. There
was a time-dependent increase in calcium, regardless of ox-
ygen status, for microbeads cultured for 21 days under
control or osteogenic conditions, which displayed marked
increases in calcium content (into the range of 400–500 mg),
compared with day 1. In contrast, microbead samples
FIG. 3. Cell viability of
fresh BMMC- and MSC-mi-
crobeads at day 1. BMMC-
microbeads were cultured in
normoxia (A–C) in (A) MSC
growth media, (B) osteogenic
media, and (C) chondrogenic
media, or hypoxia (D–F) in
(D) MSC growth media, (E)
osteogenic media, and (F)
chondrogenic media. MSC-
microbeads were cultured in
normoxia (G–I) in (G) MSC
growth media, (H) osteogenic
media, and (I) chondrogenic
media, or hypoxia ( J–L) in ( J)
MSC growth media, (K) os-
teogenic media, and (L)
chondrogenic media. Scale
bar = 200 mm. Images best
viewed in color. Color images
available online at www
.liebertpub.com/tea
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cultured in chondrogenic media did result in statistically
significant change in calcium levels, compared with day 1.
Calcium levels in osteogenic media were not different from
those in control media at day 21.
Quantification of total osteocalcin protein
from microbead samples
Figure 7 shows the total osteocalcin protein content (in ng)
measured in BMMC- and MSC-microbeads cultured in ei-
ther control MSC growth media (Fig. 7A) or osteogenic
media (Fig. 7B), in either normoxia or hypoxia. In BMMC-
microbeads, initial osteocalcin levels at day 1 were main-
tained until day 21, regardless of oxygen status. (Fig. 7A, B).
MSC-microbeads cultured in control media (Fig. 7A) in ei-
ther normoxic or hypoxic conditions exhibited a significant
increase in osteocalcin from day 1 to 21, while those mi-
crobeads cultured in osteogenic media (Fig. 7B) did not show
a statistically significant osteocalcin level increase. Osteo-
calcin levels in BMMC-microbeads and MSC-microbeads
cultured in control media were not statistically different from
each other (in the range of 300–400 ng) at day 21.
Quantification of total sGAG from microbead samples
Figure 8 shows the total sGAG content measured in
BMMC- and MSC-microbeads cultured in normoxia or
hypoxia, in either control MSC growth media (Fig. 8A) or
chondrogenic media (Fig. 8B). There were no significant
increases in sGAG levels by day 21, relative to day 1, for
any microbead culture condition. BMMC-microbeads cul-
tured for 21 days in control media (Fig. 8A) or chondrogenic
media (Fig. 8B), regardless of oxygen status, resulted in
significantly higher amounts of total sGAG content, com-
pared with MSC-microbeads. However, it should be noted
that cell viability in day 21 samples varied greatly, as
shown in Table 1. In particular, the cells within BMMC-
microbeads cultured in control media were at least 61%
alive at day 21, whereas the majority of cells cultured in
chondrogenic media were not viable. The cells in
FIG. 4. Cell viability of
BMMC-microbeads and
MSC-microbeads at day 21.
BMMC-microbeads were
cultured in normoxia (A–C)
in (A) MSC growth media,
(B) osteogenic media, and
(C) chondrogenic media, or
hypoxia (D–F) in (D) MSC
growth media, (E) osteo-
genic media, and (F) chon-
drogenic media. MSC-
microbeads were cultured in
normoxia (G–I) in (G) MSC
growth media, (H) osteo-
genic media, and (I) chon-
drogenic media, or hypoxia
( J–L) in ( J) MSC growth
media, (K) osteogenic media,
and (L) chondrogenic media.
Scale bar= 200mm. Images
best viewed in color. Color
images available online at
www.liebertpub.com/tea
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MSC-microbeads maintained their viability at about 70% in
all conditions at day 21.
Histology
BMMC- and MSC-microbeads cultured in normoxia or
hypoxia, and cultured in control MSC growth media, oste-
ogenic media, or chondrogenic media, were sectioned and
stained with H&E, Alizarin Red, von Kossa stain, and saf-
ranin-O/fast green. Eosin stained the microbead matrix pink,
and hematoxylin stained cell nuclei blue. Little to no staining
with Alizarin Red or von Kossa, indicative of calcium de-
posits and phosphate mineralization, was observed in
BMMC-microbeads or MSC-microbeads cultured in control
MSC growth media for 21 days (Fig. 9A, C), either in nor-
moxic or hypoxic conditions. In contrast, strong positive
staining for Alizarin Red and von Kossa was displayed by
both BMMC-microbeads and MSC-microbeads cultured in
osteogenic media for 21 days (Fig. 9B, D), either in nor-
moxia or hypoxia. The calcium assay using OCPC method
(Fig. 6) reacts with calcium ions, whereas the Alizarin Red S
staining reacts with calcium salts (calcium phosphate and
calcium carbonate) in histological tissue sections. Although
the results of the OCPC calcium assay display similar high
levels of calcium for samples cultured in either growth
media or osteogenic media for 21 days, strong staining by
Alizarin Red S was evident in samples cultured in osteo-
genic media, but not samples cultured in MSC growth
media. This result suggests that osteogenic supplements in
media are necessary for the formation of true mineral de-
posits containing both calcium and phosphate. Microbeads
cultured in any condition did not stain positive for safranin-
O (not shown), and microbeads cultured in chondrogenic
media showed no presence of Alizarin Red or von Kossa
staining (not shown).
Discussion
The major objective of this work was to compare the os-
teogenic and chondrogenic potential of fresh uncultured
BMMC to that of purified, culture-expanded MSC when
encapsulated in 3D collagen-chitosan microbeads. Our
overall hypothesis was that the varied and potent mixture of
cells that make up marrow would have positive effects on
the relatively small MSC fraction, and in particular would
potentiate their ability to undergo osteogenesis when em-
bedded in 3D collagen-chitosan matrices. Interestingly, our
study showed that fresh uncultured BMMC exhibited a
similar degree of osteogenesis as culture-expanded MSC
when cultured in collagen-chitosan microbeads for 21 days,
as assessed by calcium deposition, osteocalcin expression,
and histological analysis. However, chondrogenic potential
FIG. 5. Total DNA content
from microbead samples.
BMMC-microbead samples
were cultured in (A) MSC
growth media (n = 4), (B) os-
teogenic media (n= 4), or (C)
chondrogenic media (n = 4).
MSC-microbead samples
were cultured in (D) MSC
growth media (n = 4), (E) os-
teogenic media (n= 4), or (F)
chondrogenic media (n = 4).
Bars represent mean–
standard deviation (SD).
FIG. 6. Total calcium con-
tent from microbead samples.
Microbead samples were
cultured in (A) MSC growth
media (n = 4), (B) osteogenic
media (n = 4), or (C) chon-
drogenic media (n = 4). Bars
represent mean – SD.
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was not supported for either cell preparation type in colla-
gen-chitosan microbeads over 21 days.
Differential counts reveal that the cells in normal rat
bone marrow include myeloid cells (& 44%), erythroid cells
(& 36%), lymphocytes (& 19%), and plasma cells (& 0.4%).63
The abundant RBC fraction may inhibit nutrition and initial
proliferation of MSC, and therefore we used an ammonium
chloride buffer solution to lyse and remove the majority of
erythrocytes from the fresh marrow isolate, which may also
result in more remaining platelets and platelet-derived growth
factor.55–57 The remaining BMMC preparation therefore con-
sisted of a heterogenous population of cells, including MSC,
HSC/HPC, EPC, adipocytes, macrophages, monocytes, neu-
trophils, and platelets. These components can secrete a variety
of cytokines and growth factors, and may work in concert
through paracrine signaling to enhance bone formation.64 In
particular, it has been reported that HSC and other hemato-
poietic-lineage cells can enhance survival and proliferation of
bone marrow-derived CFU-F and CFU-O in vitro,24,65 and
significantly stimulate osteogenesis.24–25
MSC are a rare population of cells within human bone
marrow. Their frequency is reported to be in the range of
0.01%–0.001% of BMMC,1,5,30 although the clonogenicity of
human marrow aspirates can be variable and significantly
correlated to the age of the donor.30,66 In the present work,
the prevalence of MSC in rat marrow was found to be about
0.002%. Therefore, the overall conclusion from this study
that fresh BMMC-microbeads and culture-expanded MSC-
microbeads exhibit a similar extent of osteogenic potential is
remarkable, since the heterogenous BMMC group contained
only about 1/10th the number of MSC as the purified MSC
group. These results suggest that there is a synergistic effect
between the non-MSC component of the BMMC preparation
and the small MSC fraction. Our data suggest that the
number of MSC in both microbead types increased over time
in culture, while the non-MSC fraction decreased. The rela-
tive influence of proliferation and potentiation of differenti-
ation on osteogenesis was not independently examined,
however it was clear that the presence of the supporting cells
of BMMC played a role in improving osteogenic function.
This study also examined the effect of low oxygen tension
(5%), relative to the standard level of oxygen in vitro (20%) on
cell encapsulation and function. Hypoxia significantly in-
creased initial colony number derived from freshly isolated
rat BMMC. In microbeads, it was observed that hypoxia
enhanced initial survival and number of bone marrow pro-
genitor cells, but did not enhance osteogenic or chondrogenic
potential in either BMMC- or MSC-microbeads. Hypoxic
culture has been shown to enhance chondrogenic differen-
tiation of MSC,54–55 but the effects of hypoxic culture on
osteogenic differentiation are still not fully understood, and
are highly dependent on the concentration of oxygen, dura-
tion of hypoxia, and source and cell seeding densities of MSC,
and other factors. Several studies have suggested that hypoxic
culture inhibits osteogenic differentiation of MSC,67–71 while
others have determined that hypoxia can enhance osteogenic
differentiation of MSC.47,52,53 Our results indicate that initial
hypoxic culture (first 4 days) of freshly isolated BMMC can
enhance the survival and proliferation of fresh MSC, but that
longer term (21 days) constant hypoxia may not be benefi-
cial to osteogenic differentiation. The timing and duration of
hypoxic culture of freshly isolated BMMC must be
FIG. 7. Total osteocalcin protein
from microbead samples. Microbe-
ad samples were cultured in either
(A) MSC growth media (n = 2) or
(B) osteogenic media (n = 4). Bars
represent mean – standard error of
the mean (SEM).
FIG. 8. Total Sulfated glycosami-
noglycan (sGAG) from microbead
samples. Microbead samples were
cultured in either (A) MSC growth
media (n = 2) or (B) chondrogenic
media (n = 4). Bars represent
mean – SEM.
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considered in future studies for optimal osteogenic and
chondrogenic differentiation.
Under the conditions tested in this study, neither BMMC-
nor MSC-microbeads supported chondrogenesis. One reason
for this finding may have been the low MSC seeding density
that was used, relative to most studies investigating 3D
chondrogenesis using progenitor cells. It has been reported
that chondrogenic differentiation, specifically within colla-
gen-based microspheres, requires a high cell seeding density
to promote required cell–cell interactions and significant
sGAG deposition.44,72 We seeded culture-expanded MSC at a
concentration of 5· 105 cells/mL, and the estimated initial
concentration of MSC in the fresh BMMC preparation was
about 5 · 104 cells/mL. These cell concentrations are at least
an order of magnitude lower than the values typically used
in pellet culture and other forms of high density cartilage
tissue engineering. This issue complicates the use of fresh
BMMC preparations for cartilage applications, though it
should be noted that whole or concentrated uncultured bone
marrow has been used to successfully repair osteochondral
defects.73 Another reason for the lack of chondrogenesis in
our study may have been the matrix formulation, which
consisted of 35% chitosan and 65% collagen Type I. Chitosan
has structural properties similar to cartilage-specific GAG,
and chitosan-based scaffolds have been shown to be sup-
portive of chondrogenic differentiation of MSC.74–75 How-
ever, the molecular weight, degree of deacetylation,
viscosity, and concentration of chitosan are likely to be im-
portant factors in determining the survival, proliferation, and
chondrogenic differentiation of MSC in such hydrogels. Al-
ginate, another polysaccharide material used for tissue en-
gineering, has been shown to support chondrogenesis of
MSC both in vitro76–78 and in vivo.79 Collagen Type I is not a
main component of normal hyaline cartilage, and collagen
Type II is more typically associated with this tissue. It has
been reported that collagen Type II hydrogels resulted in the
more prominent chondrogenic differentiation of MSC,80
compared to alginate or collagen Type I. Further, collagen
Type II coatings on alginate microbeads81 or chitosan fibrous
scaffolds82 can enhance MSC proliferation and chondrogen-
esis. It is likely that a higher MSC concentration and a matrix
formulation more conducive to chondrogenesis would be re-
quired to create microbeads for cartilage tissue engineering.
The hydrogel microbead format offers several advantages
for encapsulation, culture, and delivery of progenitor cells
for orthopedic tissue engineering. In the case of freshly iso-
lated BMMC, the freshly harvested marrow cells can be di-
rectly embedded within 3D protein microbeads without
being exposed to 2D adherent culture, which can negatively
affect progenitor cell properties. Purified MSC can be ex-
panded in 2D culture, but can then also be embedded in
microbeads for further culture in a more physiological en-
vironment. The microbeads used in this study were fabri-
cated to have diameters in the range 100–200 mm, which
ensures that the maximum diffusion length for nutrients and
oxygen to the cells is at most 100 mm, well within the range
found in metabolically active tissues.83 Batches of cell-
encapsulating collagen-chitosan microbeads can be easily
fabricated by emulsification, cultured in suspension, and
then collected for cell delivery. Concentration of microbead
preparations produces cohesive pastes or constructs that can
be formed into a variety of shapes and sizes, and can be
tailored to fit a specific defect.38 Our choice of a 35% chit-
osan/65% collagen matrix in this study reflects the estab-
lished value of these materials in orthopedic tissue
engineering, and resulted in robust and stable microbeads
FIG. 9. Histology. Sections (7 mm) of BMMC-microbeads cultured in (A) MSC growth media or (B) osteogenic media, or
MSC-microbeads cultured in (C) MSC growth media or (D) osteogenic media, for 21 days either in normoxia or hypoxia.
Sections were stained with hematoxylin and eosin (H&E), Alizarin Red S, or von Kossa. Scale bar = 200 mm. Images best
viewed in color. Color images available online at www.liebertpub.com/tea
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that retained their morphology over time in culture. In par-
ticular, the collagen component provides contact with a na-
tive ECM protein that regulates the adhesion, proliferation,
and differentiation of MSC.35,36,42–44,46,84,85 Chitosan is a
naturally derived polysaccharide that provides mechanical
stability to the microbeads, and it also has been widely used
in orthopedic applications.40,41,86,87
In conclusion, this study has demonstrated that both un-
purified fresh bone marrow preparations, and purified and
culture-expanded MSC can be encapsulated in protein-
polysaccharide microbeads. Further, the data show that un-
purified BMMC have osteogenic potential similar to that of
purified MSC, even though the unpurified preparations ini-
tially contain far fewer mesenchymal progenitor cells. These
results suggest new approaches to treating bone defects, and
in particular those that may benefit from the paracrine con-
tribution of the totality of the cells in marrow, for example,
in cases where robust vascularization is required to pro-
mote healing. Future studies will include evaluation of the
bone regeneration capability of such microbeads in relevant
bone defect models in vivo.
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